Telix prostate cancer therapy data to be presented at ASCO 2026

April 21, 2026 4:49 PM

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that safety and tolerability data from Part 1 of its ProstACT Global ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found